Circulating tumor cells (CTCs) are rare in healthy individuals and patients with nonmalignant diseases, however, they are present in patients with various metastatic carcinomas. Some clinical studies indicate the number of CTCs present in the patient is an indicator of progression-free and overall survival for cancer patients. Therefore, evaluating CTCs can assist physicians to monitor and predict cancer progression for those with metastatic cancer.

This White Paper Showcase is brought to you by LabCorp Clinical Trials.

**Attendee badges scanned for this White Paper Showcase will be shared with the company hosting this offering. If you prefer to not have your badge scanned, please inform the DIA staff member.